Share price
₹264.48 latest close · −26.3% over the last 90 sessions
₹264.48 month-end · +21.7% over 12 months
52-week range ₹171.51 to ₹371.55 · 1-year volatility 52.0%
Was the rally earned?
Mostly yes, with a catch.
- Per-share earnings added 84 points, but investors now pay less per rupee of profit (P/E 24.4x to 13.9x), which took 62 points back.
- The share count rose 17%.
What do "pts" mean?
"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.
Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.
Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.
Net profit is trailing twelve months as reported with a 60-day lag.
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-37.3% (2026-07 peak to 2026-10 low, not yet recovered)
-28.7% (2025-12 peak to 2025-12 low, recovered 2026-04)
Most recent volume spikes
2026-10-15: 7.7x the 50-day median, price -5.8% that day
2026-09-21: 7.1x the 50-day median, price +3.8% that day
2026-07-16: 7.7x the 50-day median, price +8.2% that day
Where does it rank among Producer Manufacturing peers?
Each cell is the company's percentile rank among its Producer Manufacturing peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE97th▲ 12 pts vs a year ago
- Op. margin99thflat vs a year ago
- Revenue growth96th
- EPS growth91st
- Debt/equity ↓69th▲ 67 pts vs a year ago
- Cash cycle ↓34th▼ 6 pts vs a year ago
- P/E ↓85th▲ 19 pts vs a year ago
- 12M momentum74th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Producer Manufacturing sector page Watch it move against Producer Manufacturing in the Observatory
What is the price implying?
At normalised P/E (five-year average earnings) of 59.1x, a holder earning 12%/yr needs earnings to grow about 28.5%/yr for 10 years, then trade at 15x.
Over time
Implied growth by month (solid) and delivered growth (dashed).
Change the assumptions
| Exit P/E / return | 11% | 12% | 13% |
|---|---|---|---|
| 12x | 30.2% | 31.4% | 32.5% |
| 15x | 27.3% | 28.5% | 29.6% |
| 20x | 23.7% | 24.8% | 25.9% |
Drag a slider to test other assumptions
Implied: 28.5%/yr“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.
What prices imply across Producer Manufacturing The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹264.48
- P/E
- 13.9x
- ROCE
- 45.0%
- Market Cap
- ₹18311 cr
- Revenue (TTM)
- ₹5578 cr
- P/S
- 3.3x
- P/B
- 5.0x
- ROE
- 35.6%
- Operating Margin
- 35.0%
- Debt / Equity
- 0.1x
- Promoter Holding
- 80.0%
- 12M Momentum
- 21.7%
52-week range
Price risk
Balance sheet & cash
Are profits backed by cash?
Other income reliance4%Within range
Other income as a share of pre-tax profit (trailing twelve months): 3.5%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate19%Within range
Median quarterly effective tax rate over about 2.5 years: 19.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.
Cash conversion0.72xNear threshold
Operating cash flow divided by net profit over the last three fiscal years: 0.72x (cash from operations ₹1,059 cr, net profit ₹1,480 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.
Free cash flow1 of 5 yrsBeyond threshold
Fiscal years with positive free cash flow in the last 5: 1. Bands: at least 80% of years, 40% to 80%, below 40%.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress0% of fixed assetsWithin range
Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like EMMVEE PHOTOVOLTAIC POWER LIMI today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −34% to +8% vs the market, against −4% for all non-financial companies in the same months.
- The analogs' median sat below that base rate (gap −14.7%, 80% range −24.7% to −6.9%), but the matches cluster in only 6 distinct 12-month windows.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 34 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| SHAKTIPUMP Producer Manufacturing |
Aug 2025 | 24x | 55% | +8% | −40% | −44% |
| MARKSANS Health Technology |
Jun 2021 | 15x | 38% | +168% | −9% | −50% |
| RSYSTEMS Technology Services |
Mar 2022 | 21x | 36% | +124% | −24% | +6% |
| CAPLIPOINT Health Technology |
Nov 2020 | 17x | 33% | +56% | −22% | +8% |
| MANINFRA Finance |
May 2024 | 27x | 32% | +104% | −21% | −17% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| EMSLIMITED Industrial Services |
Apr 2025 | 18x | 29% | +31% | −38% | −46% |
| RUPA Consumer Non-Durables |
Sep 2021 | 20x | 30% | +134% | −16% | −29% |
| NEULANDLAB Health Technology |
Jul 2024 | 37x | 33% | +152% | −3% | +61% |
How reliable is this?
Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
What else looks like this?
Companies with the most similar financial profile today, regardless of industry.
Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.
What changed?
11 events since Dec '25
- NovDebtDebt / equity halved over 12 months to 0.10x.
- NovSharesShare count is up 200.0% over 12 months.
- OctPriceFell 37% from the Jul 2026 peak to the Oct 2026 low.
- OctPriceVolume reached 7.7x its 50-day median on 2026-10-15; price -5.8% that day.
- SepInstitutionsFII + DII holding fell 3.7 pts over 2 quarters to 12.7%.
- JulPriceVolume reached 7.7x its 50-day median on 2026-07-16; price +8.2% that day.
- JunDebtDebt / equity fell below 1.0x (0.10x).
- JunDividendStarted paying a dividend (payout 6% of profit).
Show 3 earlier events
- AprPriceRegained the 2025-12 peak, 4 months after the low.
- AprPriceVolume reached 10.9x its 50-day median on 2026-04-29; price +6.8% that day.
- DecPriceFell 29% from the Dec 2025 peak to the Dec 2025 low.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history13 months · 2025-11 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | 13.9x | ₹5578 cr | 35.6% | 45.0% | 0.1x |
| 2026-10 | 12.1x | ₹5578 cr | 34.5% | 45.0% | 0.1x |
| 2026-09 | 16.6x | ₹5578 cr | 34.5% | 45.0% | 0.1x |
| 2026-08 | 19.3x | ₹5050 cr | 29.3% | 45.0% | 0.1x |
| 2026-07 | 19.1x | ₹5050 cr | 29.3% | 45.0% | 0.1x |
| 2026-06 | 20.6x | ₹5050 cr | 29.3% | 45.0% | 0.1x |
| 2026-05 | 22.5x | ₹4383 cr | 167.0% | 28.0% | 3.8x |
| 2026-04 | 18.1x | ₹4383 cr | 167.0% | 28.0% | 3.8x |
| 2026-03 | 15.0x | ₹4383 cr | 167.0% | 28.0% | 3.8x |
| 2026-02 | 15.8x | ₹3759 cr | 136.3% | 28.0% | 3.8x |
| 2026-01 | 15.5x | ₹3759 cr | 136.3% | 28.0% | 3.8x |
| 2025-12 | 15.6x | ₹3759 cr | 136.3% | 28.0% | 3.8x |
| 2025-11 | 24.4x | ₹3030 cr | 98.5% | 28.0% | 3.8x |